|
Prostate cancer recurrent
|
0.100 |
Biomarker
|
disease |
BEFREE |
Radio-recurrent prostate cancer is typically detected by a rising PSA and may reflect local or distant disease.
|
31730876 |
2020 |
|
Prostate cancer recurrent
|
0.100 |
Biomarker
|
disease |
BEFREE |
The PSMA positivity rate for PC was significantly higher in dPET/CT for the lowest PSA values (PSA < 2.0 ng/ml, p < 0.05).
|
31792572 |
2020 |
|
Prostate cancer recurrent
|
0.100 |
Biomarker
|
disease |
BEFREE |
The primary outcome measure was to determine the relationship between pre-scan PSA and the probability of identifying PSMA-avid disease suggestive of recurrent prostate cancer.
|
31363165 |
2019 |
|
Prostate cancer recurrent
|
0.100 |
Biomarker
|
disease |
BEFREE |
18F-Fluciclovine PET/CT Detection of Recurrent Prostate Carcinoma in Patients With Serum PSA ≤ 1 ng/mL After Definitive Primary Treatment.
|
30589673 |
2019 |
|
Prostate cancer recurrent
|
0.100 |
Biomarker
|
disease |
BEFREE |
<sup>68</sup>Ga-PSMA-11 PET/CT in recurrent prostate cancer: efficacy in different clinical stages of PSA failure after radical therapy.
|
30350010 |
2019 |
|
Prostate cancer recurrent
|
0.100 |
Biomarker
|
disease |
BEFREE |
Effect of early salvage radiotherapy at PSA < 0.5 ng/ml and impact of post-SRT PSA nadir in post-prostatectomy recurrent prostate cancer.
|
30487644 |
2019 |
|
Prostate cancer recurrent
|
0.100 |
Biomarker
|
disease |
BEFREE |
68Ga-PSMA PET/CT Urachus Metastases in Recurrent Prostate Cancer With Very Low PSA Level.
|
30540597 |
2019 |
|
Prostate cancer recurrent
|
0.100 |
Biomarker
|
disease |
BEFREE |
Local recurrent prostate cancer after radical treatment is found in the majority of men with a rising PSA.
|
30788590 |
2019 |
|
Prostate cancer recurrent
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Our data show that <sup>68</sup>Ga-PSMA-11 PET/MRI has a high detection rate for recurrent prostate cancer even at very low PSA levels <0.5 ng/mL.
|
29032394 |
2018 |
|
Prostate cancer recurrent
|
0.100 |
Biomarker
|
disease |
BEFREE |
Prostatic acid phosphatase (PAP) is a prostate tumor antigen, and the target of the only FDA-approved anti-tumor vaccine, sipuleucel-T. We have previously reported in two clinical trials that a DNA vaccine encoding PAP (pTVG-HP) could elicit PAP-specific, Th1-biased T cells in patients with PSA-recurrent prostate cancer.
|
29534736 |
2018 |
|
Prostate cancer recurrent
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thirty patients (median prostate-specific antigen [PSA: 11.8 ng/mL]) with suspected recurrent prostate cancer following definitive treatment underwent <sup>11</sup>C-choline PET/CT and conventional imaging, including pelvic MRI, contrast-enhanced chest, abdomen, and pelvic CT, and bone scintigraphy.
|
30210954 |
2018 |
|
Prostate cancer recurrent
|
0.100 |
Biomarker
|
disease |
BEFREE |
Further optimization of the tumor-to-background contrast might significantly enhance the sensitivity of PET/CT imaging and the probability of detecting recurrent prostate cancer at low PSA values.
|
28787147 |
2017 |
|
Prostate cancer recurrent
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We treated 20 patients who had recurrent prostate cancer with 200 μmoles/day of sulforaphane-rich extracts for a maximum period of 20 weeks and determined the proportion of patients with ≥50% PSA declines, the primary endpoint.
|
25431127 |
2015 |
|
Prostate cancer recurrent
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Metastasis-free survival is associated with overall survival in men with PSA-recurrent prostate cancer treated with deferred androgen deprivation therapy.
|
23946329 |
2013 |
|
Prostate cancer recurrent
|
0.100 |
Biomarker
|
disease |
BEFREE |
We evaluated the efficacy of isoflavone in patients with PSA recurrent prostate cancer after prior therapy.
|
18471323 |
2008 |